TD Asset Management
BCRX icon

TD Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

TD Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-302,724
Closed -$2.31M – 1274
2024
Q3 		$2.31M Buy
302,724
+62,124
+26% +$472K ﹤0.01% 983
2024
Q2 		$1.49M Buy
+240,600
New +$1.33M ﹤0.01% 1077
2016
Q1 		– Sell
-20,100
Closed -$207K – 1360
2015
Q4 		$207K Sell
20,100
-14,100
-41% -$140K ﹤0.01% 1306
2015
Q3 		$390K Buy
+34,200
New +$456K ﹤0.01% 1139
2014
Q2 		– Sell
-33,700
Closed -$357K – 1287
2014
Q1 		$357K Buy
+33,700
New +$359K ﹤0.01% 1115

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TD Asset Management's BCRX Position: Q4 2024 in Review

TD Asset Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 302,724 shares — an estimated $2.31M sold.

TD Asset Management first reported a position in BCRX in Q1 2014 and held it in 5 quarters. The position peaked at $2.31M in Q3 2024. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • TD Asset Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • TD Asset Management sold 302,724 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $2.31M.
  • TD Asset Management first reported a position in BioCryst Pharmaceuticals in Q1 2014 and held it in 5 quarters.
  • TD Asset Management's BioCryst Pharmaceuticals position peaked at $2.31M in Q3 2024.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on TD Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.